Article

Private equity and ophthalmology: Will I be left behind?

Conferences|GLAUCOMA 360

If you find yourself waffling back and forth on private equity, Ruth D. Williams, MD, has some guidance tips to make the decision easier. 

Ruth D. Williams, MD, shares the take-home message from her presentation, "Private Equity and Ophthalmology: Will I Be Left Behind?" at the 23rd annual Glaucoma 360 meeting at the Palace Hotel in San Francisco on Feb. 2, 2019.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
Related Content
Potential biomarkers of primary open-angle glaucoma in patient serum in Nigeria
April 23rd 2025

Potential biomarkers of primary open-angle glaucoma in patient serum in Nigeria

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Study finds knowledge gaps in public understanding of glaucoma and cataracts
April 16th 2025

Study finds knowledge gaps in public understanding of glaucoma and cataracts

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Santen receives marketing authorization application approval from NMPA of China for tafluprost/timolol maleate (Tapcom) in patients with open-angle glaucoma
April 7th 2025

Santen receives marketing authorization application approval from NMPA of China for tafluprost/timolol maleate (Tapcom) in patients with open-angle glaucoma

Avisi Technologies releases 6-month interim results from VITA trial
April 4th 2025

Avisi Technologies releases 6-month interim results from VITA trial

© 2025 MJH Life Sciences

All rights reserved.